

Brian I Rini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3454558/publications.pdf>

Version: 2024-02-01

400
papers

50,885
citations

2802

94
h-index

1676

214
g-index

409
all docs

409
docs citations

409
times ranked

32768
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 378, 1277-1290.	27.0	3,334
2	Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1116-1127.	27.0	2,319
3	Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1103-1115.	27.0	1,824
4	Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 5794-5799.	1.6	1,751
5	Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. <i>Lancet, The</i> , 2011, 378, 1931-1939.	13.7	1,663
6	Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 16-24.	1.6	1,590
7	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , 2020, 395, 1907-1918.	13.7	1,395
8	Renal cell carcinoma. <i>Lancet, The</i> , 2009, 373, 1119-1132.	13.7	1,363
9	Sunitinib in Patients With Metastatic Renal Cell Carcinoma. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 2516.	7.4	1,111
10	Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2015, 373, 1814-1823.	27.0	1,004
11	Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1430-1437.	1.6	914
12	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. <i>Nature Medicine</i> , 2018, 24, 749-757.	30.7	900
13	Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206. <i>Journal of Clinical Oncology</i> , 2008, 26, 5422-5428.	1.6	874
14	External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. <i>Lancet Oncology, The</i> , 2013, 14, 141-148.	10.7	808
15	Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients. <i>Clinical Cancer Research</i> , 2009, 15, 2148-2157.	7.0	792
16	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2016, 17, 917-927.	10.7	789
17	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. <i>Lancet, The</i> , 2019, 393, 2404-2415.	13.7	778
18	Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206. <i>Journal of Clinical Oncology</i> , 2010, 28, 2137-2143.	1.6	746

#	ARTICLE	IF	CITATIONS
19	Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 552-562.	10.7	640
20	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1370-1385.	10.7	594
21	Treatment of renal cell carcinoma: Current status and future directions. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 507-524.	329.8	583
22	Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. <i>Journal of the National Cancer Institute</i> , 2011, 103, 763-773.	6.3	526
23	Resistance to targeted therapy in renal-cell carcinoma. <i>Lancet Oncology</i> , The, 2009, 10, 992-1000.	10.7	496
24	Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1563-1573.	10.7	466
25	Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients. <i>Clinical Cancer Research</i> , 2008, 14, 6674-6682.	7.0	444
26	Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. <i>Lancet Oncology</i> , The, 2007, 8, 975-984.	10.7	428
27	Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity. <i>European Urology</i> , 2015, 67, 85-97.	1.9	403
28	Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma. <i>Cancer Research</i> , 2010, 70, 1063-1071.	0.9	394
29	A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 1810-1815.	7.0	385
30	Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3851-3858.	1.6	384
31	Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology</i> , 2014, 66, 704-710.	1.9	382
32	Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 3743-3748.	1.6	381
33	Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 127-131.	1.6	373
34	Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. <i>Journal of the National Cancer Institute</i> , 2007, 99, 81-83.	6.3	370
35	Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. <i>ESMO Open</i> , 2020, 5, e001079.	4.5	343
36	Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 4462-4468.	1.6	323

#	ARTICLE	IF	CITATIONS
37	Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3916-3923.	1.6	316
38	HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism. <i>Nature Communications</i> , 2017, 8, 1769.	12.8	303
39	The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. <i>Lancet Oncology</i> , The, 2015, 16, 293-300.	10.7	299
40	Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2011, 13, 591-599.	1.2	295
41	Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2 α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 867-874.	1.6	290
42	Direct and Differential Suppression of Myeloid-Derived Suppressor Cell Subsets by Sunitinib Is Compartmentally Constrained. <i>Cancer Research</i> , 2010, 70, 3526-3536.	0.9	269
43	Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. <i>Cancer Cell</i> , 2020, 38, 803-817.e4.	16.8	262
44	MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. <i>International Immunopharmacology</i> , 2011, 11, 856-861.	3.8	257
45	Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF. <i>Cancer Research</i> , 2009, 69, 609-615.	0.9	238
46	HIF Inhibitors: Status of Current Clinical Development. <i>Current Oncology Reports</i> , 2019, 21, 6.	4.0	230
47	A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. <i>Lancet Oncology</i> , The, 2015, 16, 676-685.	10.7	229
48	The immunology of renal cell carcinoma. <i>Nature Reviews Nephrology</i> , 2020, 16, 721-735.	9.6	229
49	Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. <i>Lancet Oncology</i> , The, 2018, 19, 451-460.	10.7	228
50	Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. <i>Cancer Discovery</i> , 2020, 10, 40-53.	9.4	219
51	Renal Angiomyolipoma. <i>American Journal of Surgical Pathology</i> , 2009, 33, 289-297.	3.7	216
52	Morphology, Attenuation, Size, and Structure (MASS) Criteria: Assessing Response and Predicting Clinical Outcome in Metastatic Renal Cell Carcinoma on Antiangiogenic Targeted Therapy. <i>American Journal of Roentgenology</i> , 2010, 194, 1470-1478.	2.2	216
53	Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. <i>Lancet Oncology</i> , The, 2013, 14, 1233-1242.	10.7	215
54	Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Therapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 235-241.	1.6	214

#	ARTICLE	IF	CITATIONS
55	Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy. <i>European Urology</i> , 2014, 65, 577-584.	1.9	207
56	Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 297-310.	10.7	207
57	Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1317-1324.	10.7	200
58	COVID-19 and Cancer: Current Challenges and Perspectives. <i>Cancer Cell</i> , 2020, 38, 629-646.	16.8	196
59	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 2445-2452.	7.0	193
60	Metastatic nonâ€œclear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria. <i>Cancer</i> , 2013, 119, 2999-3006.	4.1	189
61	The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). , 2019, 7, 354.		182
62	IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1599-1611.	10.7	181
63	Randomized Phase III Trial of Temeprolimus and Bevacizumab Versus Interferon Alfa and Bevacizumab in Metastatic Renal Cell Carcinoma: INTORACT Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 752-759.	1.6	179
64	Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. <i>Journal of Clinical Oncology</i> , 2016, 34, 3655-3663.	1.6	174
65	Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 3841-3849.	7.0	173
66	Allogeneic Stem-Cell Transplantation of Renal Cell Cancer After Nonmyeloablative Chemotherapy: Feasibility, Engraftment, and Clinical Results. <i>Journal of Clinical Oncology</i> , 2002, 20, 2017-2024.	1.6	169
67	Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. <i>Cell</i> , 2021, 184, 2988-3005.e16.	28.9	166
68	Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma: Current Status and Future Directions. <i>Clinical Cancer Research</i> , 2007, 13, 1098-1106.	7.0	161
69	Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. <i>Lancet Oncology</i> , The, 2020, 21, 95-104.	10.7	160
70	Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. , 2020, 8, e000891.		160
71	Cancer and Leukemia Group B 90206. <i>Clinical Cancer Research</i> , 2004, 10, 2584-2586.	7.0	158
72	Temeprolimus, an Inhibitor of Mammalian Target of Rapamycin. <i>Clinical Cancer Research</i> , 2008, 14, 1286-1290.	7.0	156

#	ARTICLE	IF	CITATIONS
73	Phase II Trial of Weekly Intravenous Gemcitabine With Continuous Infusion Fluorouracil in Patients With Metastatic Renal Cell Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 2419-2426.	1.6	154
74	Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression. <i>JAMA Oncology</i> , 2016, 2, 1179.	7.1	154
75	Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 78-86.	7.0	154
76	Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. , 2018, 6, 109.		151
77	Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1 β , IL8, CXCL5, and Mip-1 α . <i>Clinical Cancer Research</i> , 2017, 23, 2346-2355.	7.0	148
78	Recent Progress in the Management of Advanced Renal Cell Carcinoma. <i>Ca-A Cancer Journal for Clinicians</i> , 2007, 57, 112-125.	329.8	147
79	Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2011, 117, 758-767.	4.1	143
80	State of the Science: An Update on Renal Cell Carcinoma. <i>Molecular Cancer Research</i> , 2012, 10, 859-880.	3.4	142
81	Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. , 2018, 6, 9.		141
82	Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. <i>European Urology</i> , 2016, 70, 358-364.	1.9	133
83	Angiogenesis and the Tumor Microenvironment: Vascular Endothelial Growth Factor and Beyond. <i>Seminars in Oncology</i> , 2014, 41, 235-251.	2.2	129
84	Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. <i>International Journal of Cancer</i> , 2011, 129, 2158-2170.	5.1	127
85	ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic Disease. <i>European Urology</i> , 2011, 60, 684-690.	1.9	125
86	Sunitinib rechallenge in metastatic renal cell carcinoma patients. <i>Cancer</i> , 2010, 116, 5400-5406.	4.1	123
87	Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 491-504.	2.0	122
88	Renal cell carcinoma. <i>Current Opinion in Oncology</i> , 2008, 20, 300-306.	2.4	120
89	A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2002, 95, 1629-1636.	4.1	119
90	Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. <i>Cancer</i> , 2006, 107, 67-74.	4.1	119

#	ARTICLE	IF	CITATIONS
91	HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 793-803.	7.0	117
92	Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. <i>Cancer</i> , 2012, 118, 1946-1954.	4.1	115
93	Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. <i>Lancet Oncology</i> , The, 2012, 13, 927-935.	10.7	112
94	Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. <i>Cancer Discovery</i> , 2020, 10, 1514-1527.	9.4	108
95	Metastatic Renal Cell Carcinoma: Many Treatment Options, One Patient. <i>Journal of Clinical Oncology</i> , 2009, 27, 3225-3234.	1.6	105
96	Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. <i>BJU International</i> , 2006, 98, 756-762.	2.5	104
97	Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial. <i>Clinical Infectious Diseases</i> , 2021, 72, e835-e843.	5.8	103
98	Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. <i>Cancer</i> , 2022, 128, 2085-2097.	4.1	103
99	Randomized Open-Label Phase II Trial of Apatolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 1660-1668.	1.6	99
100	AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney. <i>Cancer</i> , 2012, 118, 6152-6161.	4.1	97
101	Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. <i>British Journal of Cancer</i> , 2015, 113, 1571-1580.	6.4	88
102	Prostate-Specific Antigen Kinetics as a Measure of the Biologic Effect of Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Serologic Progression of Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 99-105.	1.6	87
103	Sorafenib. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 453-461.	1.8	86
104	Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4500-4500.	1.6	85
105	A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 6277-6283.	7.0	84
106	Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. <i>Cancer</i> , 2009, 115, 2306-2312.	4.1	84
107	Adult Cystic Nephroma and Mixed Epithelial and Stromal Tumor of the Kidney Are the Same Disease Entity. <i>American Journal of Surgical Pathology</i> , 2009, 33, 72-80.	3.7	84
108	The Evolving Role of Surgery for Advanced Renal Cell Carcinoma in the Era of Molecular Targeted Therapy. <i>Journal of Urology</i> , 2007, 177, 1978-1984.	0.4	81

#	ARTICLE	IF	CITATIONS
109	New Strategies in Kidney Cancer: Therapeutic Advances through Understanding the Molecular Basis of Response and Resistance. <i>Clinical Cancer Research</i> , 2010, 16, 1348-1354.	7.0	80
110	A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma. <i>Journal of Urology</i> , 2015, 194, 297-303.	0.4	80
111	The Effect of Sunitinib on Primary Renal Cell Carcinoma and Facilitation of Subsequent Surgery. <i>Journal of Urology</i> , 2012, 187, 1548-1554.	0.4	79
112	Outcome of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e79-e85.	1.9	78
113	Clinical Outcome in Metastatic Renal Cell Carcinoma Patients After Failure of Initial Vascular Endothelial Growth Factor-Targeted Therapy. <i>Urology</i> , 2010, 76, 430-434.	1.0	75
114	CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2015, 68, 621-629.	1.9	75
115	Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2022, 8, 275.	7.1	75
116	Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. <i>Cancer</i> , 2011, 117, 2637-2642.	4.1	74
117	Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy. <i>European Urology</i> , 2014, 65, 1086-1092.	1.9	71
118	Prospective Clinical Study of Precision Oncology in Solid Tumors. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	6.3	70
119	The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium. <i>European Urology</i> , 2014, 65, 723-730.	1.9	69
120	Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 1386-1394.	10.7	69
121	A phase II study of gemcitabine and capecitabine in metastatic renal cancer. <i>Cancer</i> , 2006, 107, 1273-1279.	4.1	68
122	Sunitinib. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2359-2369.	1.8	66
123	Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. <i>BJU International</i> , 2010, 106, 1266-1269.	2.5	65
124	Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology</i> , 2017, 71, 204-209.	1.9	65
125	Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008, 26, 543-549.	1.6	64
126	Prognostic Factors of Survival for Patients With Metastatic Renal Cell Carcinoma With Brain Metastases Treated With Targeted Therapy: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 311-315.	1.9	64

#	ARTICLE	IF	CITATIONS
127	Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. <i>European Urology</i> , 2021, 79, 659-662.	1.9	64
128	Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. <i>Cancer</i> , 2010, 116, 5383-5390.	4.1	63
129	Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2019, 5, 411.	7.1	63
130	Molecular Biomarkers in Advanced Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 2060-2071.	7.0	62
131	Metabolism of Kidney Cancer: From the Lab to Clinical Practice. <i>European Urology</i> , 2013, 63, 244-251.	1.9	61
132	CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4513-4513.	1.6	61
133	Axitinib for renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 741-748.	4.1	60
134	Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 112.e15-112.e21.	1.6	60
135	VEGF-Targeted Therapy in Metastatic Renal Cell Carcinoma. <i>Oncologist</i> , 2005, 10, 191-197.	3.7	58
136	GD3, an Overexpressed Tumor-Derived Ganglioside, Mediates the Apoptosis of Activated but not Resting T Cells. <i>Cancer Research</i> , 2009, 69, 3095-3104.	0.9	57
137	Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. <i>British Journal of Cancer</i> , 2020, 123, 1590-1598.	6.4	57
138	Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. <i>Cancer</i> , 2006, 106, 566-575.	4.1	56
139	Antigen-Presenting Cells 8015 (Provenge®) in Patients with Androgen-Dependent, Biochemically Relapsed Prostate Cancer. <i>Clinical Prostate Cancer</i> , 2005, 4, 55-60.	2.1	55
140	Pancreatic tropism of metastatic renal cell carcinoma. <i>JCI Insight</i> , 2020, 5, .	5.0	55
141	A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. <i>BJU International</i> , 2006, 98, 763-769.	2.5	54
142	Tumor Necrosis Adds Prognostically Significant Information to Grade in Clear Cell Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2016, 40, 1224-1231.	3.7	54
143	Novel agents in renal carcinoma: a reality check. <i>Therapeutic Advances in Medical Oncology</i> , 2012, 4, 183-194.	3.2	53
144	Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2016, 69, 345-351.	1.9	53

#	ARTICLE	IF	CITATIONS
145	Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer</i> , 2018, 124, 3677-3683.	4.1	53
146	Sequencing of Agents for Metastatic Renal Cell Carcinoma: Can We Customize Therapy?. <i>European Urology</i> , 2012, 61, 307-316.	1.9	52
147	Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. <i>European Urology</i> , 2020, 77, 449-453.	1.9	52
148	Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. <i>BJU International</i> , 2005, 96, 286-290.	2.5	51
149	p53-Independent, Normal Stem Cell Sparing Epigenetic Differentiation Therapy for Myeloid and Other Malignancies. <i>Seminars in Oncology</i> , 2012, 39, 97-108.	2.2	51
150	Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma. <i>Journal of Neurosurgery: Spine</i> , 2016, 25, 766-774.	1.7	51
151	Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib. <i>Clinical Cancer Research</i> , 2018, 24, 4407-4415.	7.0	50
152	Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2019, 2, 505-514.	5.4	50
153	Neoadjuvant therapy for localized and locally advanced renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 31-37.	1.6	49
154	Elevated Levels of Select Gangliosides in T Cells from Renal Cell Carcinoma Patients Is Associated with T Cell Dysfunction. <i>Journal of Immunology</i> , 2009, 183, 5050-5058.	0.8	48
155	Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. <i>Clinical Cancer Research</i> , 2019, 25, 210-221.	7.0	48
156	The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. <i>Targeted Oncology</i> , 2013, 8, 203-209.	3.6	47
157	Adjuvant therapy in renal cell carcinoma. <i>Cancer</i> , 2019, 125, 2935-2944.	4.1	47
158	Vascular Endothelial Growth Factor–Targeted Therapies in Advanced Renal Cell Carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 813-833.	2.2	46
159	The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer. <i>Cancer Cell</i> , 2020, 37, 738-741.	16.8	46
160	Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. <i>Targeted Oncology</i> , 2015, 10, 45-53.	3.6	45
161	Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non–Clear Cell Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 429-435.	1.9	45
162	COVID-19 and immune checkpoint inhibitors: initial considerations. , 2020, 8, e000933.		45

#	ARTICLE	IF	CITATIONS
163	Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. <i>Cancer Treatment Reviews</i> , 2020, 84, 101966.	7.7	44
164	Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2020, 78, 615-623.	1.9	44
165	Toxicity of Sunitinib Plus Bevacizumab in Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2010, 28, e284-e285.	1.6	43
166	Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma. <i>Cancer</i> , 2013, 119, 313-324.	4.1	43
167	MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model. <i>British Journal of Cancer</i> , 2016, 115, 920-928.	6.4	43
168	HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 3333-3340.	8.2	43
169	Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2008, 113, 1309-1314.	4.1	42
170	Five-Year Survival in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma Treated With Axitinib. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 107-114.	1.9	42
171	COVID-19 and Cancer. <i>JAMA Oncology</i> , 2021, 7, 1882.	7.1	42
172	Castration-resistant prostate cancer: Many treatments, many options, many challenges ahead. <i>Cancer</i> , 2012, 118, 2583-2593.	4.1	41
173	Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. <i>European Urology</i> , 2015, 68, 506-515.	1.9	41
174	Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 298-304.	1.9	41
175	Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A CALGB Intergroup Phase II Study. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 778-785.	2.0	40
176	Temsirolimus. <i>Nature Reviews Drug Discovery</i> , 2007, 6, 599-600.	46.4	40
177	Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2014, 120, 52-60.	4.1	40
178	Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 405-412.	1.6	40
179	Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 499-503.	1.9	39
180	Change in Psoas Muscle Volume as a Predictor of Outcomes in Patients Treated with Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2017, 3, 57-63.	0.4	39

#	ARTICLE	IF	CITATIONS
181	The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 160-163.	6.4	39
182	Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. <i>European Urology</i> , 2021, 79, 334-338.	1.9	39
183	Patients with Metastatic Renal Cell Carcinoma with Long-Term Disease-Free Survival After Treatment with Sunitinib and Resection of Residual Metastases. <i>Clinical Genitourinary Cancer</i> , 2006, 5, 232-234.	1.9	38
184	GM1 and Tumor Necrosis Factor- α , Overexpressed in Renal Cell Carcinoma, Synergize to Induce T-Cell Apoptosis. <i>Cancer Research</i> , 2008, 68, 2014-2023.	0.9	38
185	Isolated, Primary Extranodal Hodgkin's Disease of the Spine: Case Report. <i>Neurosurgery</i> , 2001, 49, 453-457.	1.1	36
186	Biological Aspects and Binding Strategies of Vascular Endothelial Growth Factor in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 741s-746s.	7.0	36
187	Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference: Fig. 1.. <i>Clinical Cancer Research</i> , 2007, 13, 667s-670s.	7.0	36
188	A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1764-1769.	1.6	36
189	Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events. <i>British Journal of Cancer</i> , 2020, 123, 898-904.	6.4	36
190	Signal Integration and Gene Induction by a Functionally Distinct STAT3 Phosphoform. <i>Molecular and Cellular Biology</i> , 2014, 34, 1800-1811.	2.3	35
191	Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting. <i>Clinical Cancer Research</i> , 2020, 26, 2087-2095.	7.0	35
192	The Current Role of Angiogenesis Inhibitors in the Treatment of Renal Cell Carcinoma. <i>Seminars in Oncology</i> , 2006, 33, 596-606.	2.2	34
193	Impact of Neoadjuvant Chemotherapy on Pathologic Response in Patients With Upper Tract Urothelial Carcinoma Undergoing Extirpative Surgery. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1237-e1242.	1.9	34
194	A Modern Assessment of Cancer Risk in Adrenal Incidentalomas. <i>Annals of Surgery</i> , 2022, 275, e238-e244.	4.2	34
195	Molecularly targeted therapy in renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 1031-1040.	2.4	33
196	Laparoscopic versus Open Cytoreductive Nephrectomy in Advanced Renal-Cell Carcinoma. <i>Journal of Endourology</i> , 2006, 20, 504-508.	2.1	33
197	Germline and somatic DNA methylation and epigenetic regulation of <i>KILLIN</i> in renal cell carcinoma. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 654-661.	2.8	33
198	Mediators of Inflammation-Driven Expansion, Trafficking, and Function of Tumor-Infiltrating MDSCs. <i>Cancer Immunology Research</i> , 2019, 7, 1687-1699.	3.4	33

#	ARTICLE	IF	CITATIONS
199	First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. <i>European Urology</i> , 2022, 81, 266-271.	1.9	33
200	Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1929-1938.	1.6	33
201	Renal cell carcinoma. <i>Current Opinion in Oncology</i> , 2006, 18, 289-296.	2.4	32
202	Management of the small renal mass. <i>Translational Andrology and Urology</i> , 2017, 6, 923-930.	1.4	32
203	Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2134330.	5.9	32
204	Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 2662.	3.7	31
205	Prolonged Complete Responses and Near-Complete Responses to Sunitinib in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 446-451.	1.9	30
206	Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. <i>OncoTargets and Therapy</i> , 2009, 2, 51.	2.0	30
207	Noncytotoxic Differentiation Treatment of Renal Cell Cancer. <i>Cancer Research</i> , 2011, 71, 1431-1441.	0.9	30
208	Current Treatment Considerations in Metastatic Renal Cell Carcinoma. <i>Current Treatment Options in Oncology</i> , 2012, 13, 212-229.	3.0	30
209	Surgical Outcomes After Cyto-reductive Nephrectomy With Inferior Vena Cava Thrombectomy. <i>Urology</i> , 2014, 84, 1414-1419.	1.0	30
210	Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1251-1269.	3.5	29
211	A Phase I Trial of Docetaxel/Estramustine/Imatinib in Patients with Hormone-Refractory Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 323-328.	1.9	27
212	The Prognostic Significance of Epidermal Growth Factor Receptor Expression in Clear-Cell Renal Cell Carcinoma: A Call for Standardized Methods for Immunohistochemical Evaluation. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 264-270.	1.9	26
213	Efficacy of Targeted Therapy for Metastatic Renal Cell Carcinoma in the Elderly Patient Population. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 354-358.	1.9	26
214	Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. <i>Cancer Immunology Research</i> , 2016, 4, 948-958.	3.4	26
215	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. <i>Cancer Cell</i> , 2020, 38, 761-766.	16.8	26
216	Technology evaluation: APC-8015, Dendreon. <i>Current Opinion in Molecular Therapeutics</i> , 2002, 4, 76-9.	2.8	26

#	ARTICLE	IF	CITATIONS
217	A Population-Based Overview of Sequences of Targeted Therapy in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e127-e131.	1.9	25
218	Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e879-e892.	1.9	25
219	Association of PD-L1, PD-L2, and Immune Response Markers in Matched Renal Clear Cell Carcinoma Primary and Metastatic Tissue Specimens. <i>American Journal of Clinical Pathology</i> , 2019, 151, 217-225.	0.7	25
220	Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6687-6695.	7.0	25
221	Neoadjuvant Sunitinib Decreases Inferior Vena Caval Thrombus Size and Is Associated With Improved Oncologic Outcomes: A Multicenter Comparative Analysis. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e505-e512.	1.9	24
222	Prostate cancer update. <i>Current Opinion in Oncology</i> , 2002, 14, 286-291.	2.4	23
223	The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib. <i>Cancer</i> , 2011, 117, 1183-1189.	4.1	23
224	Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: A preliminary analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1283-1291.	1.6	23
225	Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma—Analysis Using Diagnostic Nodes. <i>Oncologist</i> , 2015, 20, 1028-1035.	3.7	23
226	Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e437-e442.	1.9	23
227	A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy. , 2019, 7, 127.		23
228	The COVID-19 risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2522-2532.	3.8	23
229	Immunotherapy for metastatic renal cell carcinoma. <i>BJU International</i> , 2007, 99, 1282-1288.	2.5	22
230	Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 540-547.e7.	1.9	22
231	Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. <i>Targeted Oncology</i> , 2018, 13, 599-609.	3.6	22
232	Hormone-Refractory prostate cancer. <i>Current Treatment Options in Oncology</i> , 2002, 3, 437-446.	3.0	21
233	The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy. <i>Cancer</i> , 2012, 118, 365-370.	4.1	21
234	Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study. <i>Cancer Science</i> , 2017, 108, 1231-1239.	3.9	21

#	ARTICLE	IF	CITATIONS
235	Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 413-419.e1.	1.9	21
236	Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 1031-1041.	1.3	20
237	Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2020, 78, 783-785.	1.9	20
238	Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2506-2514.	7.0	20
239	Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. <i>European Urology</i> , 2021, 79, 665-673.	1.9	20
240	A Phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma. <i>Cancer</i> , 2005, 103, 553-558.	4.1	19
241	Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2012, 118, 3277-3282.	4.1	19
242	Dual VEGF/VEGFR inhibition in advanced solid malignancies. <i>Cancer Biology and Therapy</i> , 2014, 15, 975-981.	3.4	19
243	Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1477-1484.	1.9	19
244	The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 3557-3565.	7.0	19
245	Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e275-e280.	1.9	19
246	Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. <i>BJU International</i> , 2020, 126, 73-82.	2.5	19
247	Severity of illness scores at presentation predict ICU admission and mortality in COVID-19. <i>Journal of Emergency and Critical Care Medicine</i> , 2021, 5, 7-7.	0.7	19
248	COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021, 155, 291-293.	2.8	19
249	Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial. <i>BJU International</i> , 2011, 107, 562-570.	2.5	18
250	Differing Von Hippel Lindau Genotype in Paired Primary and Metastatic Tumors in Patients with Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2012, 2, 51.	2.8	18
251	A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma. <i>Cancer</i> , 2019, 125, 2400-2408.	4.1	18
252	Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. <i>ESMO Open</i> , 2020, 5, e000852.	4.5	18

#	ARTICLE	IF	CITATIONS
253	MBOAT7-driven phosphatidylinositol remodeling promotes the progression of clear cell renal carcinoma. <i>Molecular Metabolism</i> , 2020, 34, 136-145.	6.5	18
254	Pazopanib for the treatment of renal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1171-1189.	1.8	17
255	Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib. <i>Targeted Oncology</i> , 2016, 11, 229-234.	3.6	17
256	Prognostic Factors and Risk Stratification in Invasive Upper Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e751-e760.	1.9	17
257	Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial. <i>European Urology Oncology</i> , 2022, 5, 225-234.	5.4	17
258	SU11248 and AG013736: Current Data and Future Trials in Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2005, 4, 175-180.	1.9	16
259	Current status and future directions of molecular markers in renal cell carcinoma. <i>Current Opinion in Urology</i> , 2006, 16, 332-336.	1.8	16
260	Clinical Activity of Sorafenib and Sunitinib in Renal Cell Carcinoma Refractory to Previous Vascular Endothelial Growth Factor-Targeted Therapy: Two Case Reports. <i>Clinical Genitourinary Cancer</i> , 2006, 5, 78-81.	1.9	16
261	Current Data with Mammalian Target of Rapamycin Inhibitors in Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2006, 5, 110-113.	1.9	16
262	Emerging therapeutic approaches in renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1305-1314.	2.4	16
263	Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. <i>Biomarker Research</i> , 2021, 9, 80.	6.8	16
264	Emerging therapeutics in refractory renal cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1225-1232.	1.8	15
265	Individualized dosing with axitinib: rationale and practical guidance. <i>Future Oncology</i> , 2018, 14, 861-875.	2.4	15
266	Targeted therapy in renal cell carcinoma. <i>Current Opinion in Urology</i> , 2008, 18, 481-487.	1.8	14
267	A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma. <i>Investigational New Drugs</i> , 2012, 30, 364-367.	2.6	14
268	A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer. <i>Investigational New Drugs</i> , 2013, 31, 1044-1050.	2.6	14
269	Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 403-410.e2.	1.9	14
270	Emerging immunotherapy in advanced renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 687-693.	1.6	14

#	ARTICLE	IF	CITATIONS
271	Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies. <i>Targeted Oncology</i> , 2018, 13, 353-361.	3.6	14
272	Immunotherapy for renal cell carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 897-905.	3.1	14
273	Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial Carcinoma. <i>Targeted Oncology</i> , 2020, 15, 211-220.	3.6	14
274	Care without a compass: Including patients with cancer in COVID-19 studies. <i>Cancer Cell</i> , 2021, 39, 895-896.	16.8	14
275	Renal cell carcinoma. <i>Current Opinion in Oncology</i> , 2007, 19, 234-240.	2.4	13
276	Oral enzastaurin in prostate cancer: A two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease. <i>Investigational New Drugs</i> , 2011, 29, 1441-1448.	2.6	13
277	Clinical and Immunomodulatory Effects of Celecoxib Plus Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients with COX-2 Tumor Immunostaining. <i>Journal of Clinical Immunology</i> , 2011, 31, 690-698.	3.8	13
278	Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone. <i>Anti-Cancer Drugs</i> , 2013, 24, 431-440.	1.4	13
279	A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance). <i>EBioMedicine</i> , 2015, 2, 1814-1820.	6.1	13
280	Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC). <i>Kidney Cancer</i> , 2017, 1, 41-47.	0.4	13
281	An update on prostate cancer. <i>Current Opinion in Oncology</i> , 2001, 13, 204-211.	2.4	12
282	Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon- γ in patients with metastatic renal cell carcinoma. <i>BJU International</i> , 2012, 109, 63-69.	2.5	12
283	Population Pharmacokinetic-Pharmacodynamic Modelling of 24-h Diastolic Ambulatory Blood Pressure Changes Mediated by Axitinib in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Pharmacokinetics</i> , 2015, 54, 397-407.	3.5	12
284	Prognostic implications of sarcomatoid and rhabdoid differentiation in patients with grade 4 renal cell carcinoma. <i>International Urology and Nephrology</i> , 2016, 48, 1253-1260.	1.4	12
285	The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 577-584.	2.4	12
286	Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. <i>European Urology</i> , 2017, 71, 970-978.	1.9	12
287	Drug Holiday in Metastatic Renal-Cell Carcinoma Patients Treated With Vascular Endothelial Growth Factor Receptor Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e663-e667.	1.9	12
288	Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations. <i>BMC Urology</i> , 2020, 20, 84.	1.4	12

#	ARTICLE	IF	CITATIONS
289	Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e306-e312.	1.9	12
290	Phase III AXIS trial for second-line metastatic renal cell carcinoma (mRCC): Effect of prior first-line treatment duration and axitinib dose titration on axitinib efficacy.. <i>Journal of Clinical Oncology</i> , 2012, 30, 354-354.	1.6	12
291	Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4511-4511.	1.6	12
292	Biomarkers: hypertension following anti-angiogenesis therapy. <i>Clinical Advances in Hematology and Oncology</i> , 2010, 8, 415-6.	0.3	12
293	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. <i>Clinical Cancer Research</i> , 2022, 28, 831-839.	7.0	12
294	Renal cell carcinoma. <i>Current Opinion in Oncology</i> , 2005, 17, 261-267.	2.4	11
295	VEGF-targeted therapy in renal cell carcinoma: Active drugs and active choices. <i>Current Oncology Reports</i> , 2006, 8, 85-89.	4.0	11
296	The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 113-117.	3.8	11
297	Perinephric and Sinus Fat Invasion in Stage pT3a Tumors Managed by Partial Nephrectomy. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1077-e1082.	1.9	11
298	Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy. <i>Prostate</i> , 2018, 78, 1035-1041.	2.3	11
299	Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 177-182.	1.9	11
300	Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial. <i>Clinical Cancer Research</i> , 2022, 28, 738-747.	7.0	11
301	Tumor-Infiltrating Myeloid Cells Co-Express TREM1 and TREM2 and Elevated TREM-1 Associates With Disease Progression in Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 662723.	2.8	11
302	Phase I/II Trial of 5-Fluorouracil and a Noncytotoxic Dose Level of Suramin in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2008, 6, 79-85.	1.9	10
303	The HLA-A*24-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer. <i>Prostate</i> , 2009, 69, 142-148.	2.3	10
304	Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: Results From the International mRCC Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 150-155.	1.9	10
305	Renal Functional Outcome of Partial Nephrectomy for Complex R.E.N.A.L. Score Tumors With or Without Neoadjuvant Sunitinib: A Multicenter Analysis. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e289-e295.	1.9	10
306	Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)1. <i>Kidney Cancer</i> , 2018, 2, 31-36.	0.4	10

#	ARTICLE	IF	CITATIONS
307	Myeloid-Derived Suppressor Cells in Nonmetastatic Urothelial Carcinoma of Bladder Is Associated With Pathologic Complete Response and Overall Survival. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 500-508.	1.9	10
308	Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 1475.	3.7	10
309	Targeted therapy for metastatic renal cell carcinoma: a home run or a work in progress?. <i>Oncology</i> , 2008, 22, 388-96; discussion 396, 402-3, 476 passim.	0.5	10
310	Immunotherapy for prostate cancer. <i>Current Oncology Reports</i> , 2001, 3, 418-423.	4.0	9
311	Stabilization of disease in patients with metastatic renal cell carcinoma using sorafenib. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 602-603.	4.3	9
312	Integration of surgery and systemic therapy in the management of metastatic renal cancer. <i>Current Urology Reports</i> , 2009, 10, 35-41.	2.2	9
313	The ineligible patient: how to treat patients not included in clinical studies. <i>World Journal of Urology</i> , 2014, 32, 9-18.	2.2	9
314	First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 335-340.	1.9	9
315	Urinary Biomarkers for the Detection and Management of Localized Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2015, 1, 212.	7.1	9
316	Novel Agents and Drug Development Needs in Advanced Clear Cell Renal Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 3639-3644.	1.6	9
317	Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 65-71.	1.9	9
318	Complete Pathologic Responses With Immunotherapy in Metastatic Renal Cell Carcinoma: Case Reports. <i>Frontiers in Oncology</i> , 2020, 10, 609235.	2.8	9
319	PBRM1 loss in kidney cancer unbalances the proximal tubule master transcription factor hub to repress proximal tubule differentiation. <i>Cell Reports</i> , 2021, 36, 109747.	6.4	9
320	Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab. , 2021, 9, e003281.		9
321	Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma. <i>Current Oncology Reports</i> , 2022, 24, 695-702.	4.0	9
322	Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2021, , .	1.9	9
323	Targeted therapy for patients with renal-cell carcinoma. <i>Lancet Oncology</i> , The, 2011, 12, 1085-1087.	10.7	8
324	Imaging strategy and outcome following partial nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 660.e1-660.e8.	1.6	8

#	ARTICLE	IF	CITATIONS
325	A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab. Targeted Oncology, 2021, 16, 633-642.	3.6	8
326	Axitinib with or without dose titration for first-line metastatic renal cell carcinoma (mRCC): Unblinded results from a randomized phase II study.. Journal of Clinical Oncology, 2013, 31, LBA349-LBA349.	1.6	8
327	Phase III study of the hypoxia-inducible factor 2Î± (HIF-2Î±) inhibitor MK-6482 versus everolimus in previously treated patients with advanced clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology, 2020, 38, TPS5094-TPS5094.	1.6	8
328	Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up.. Journal of Clinical Oncology, 2022, 40, 352-352.	1.6	8
329	Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNÎ± ± Bevacizumab: Results from CALGB 90206 (Alliance). Clinical Cancer Research, 2022, 28, 2771-2778.	7.0	8
330	Response: Re: Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. Journal of the National Cancer Institute, 2007, 99, 976-977.	6.3	7
331	Molecular genetics of hereditary renal cancer: new genes and diagnostic and therapeutic opportunities. Expert Review of Anticancer Therapy, 2008, 8, 895-905.	2.4	7
332	Is sorafenib plus interferon Î±2b safe and effective in patients with renal cell carcinoma?. Nature Reviews Urology, 2008, 5, 132-133.	1.4	7
333	The use of sunitinib in renal cell carcinoma: where are we now?. Expert Review of Anticancer Therapy, 2014, 14, 983-999.	2.4	7
334	A Genetic Polymorphism in <i>CTLA-4</i> Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2018, 24, 2350-2356.	7.0	7
335	Important Group Differences on the Functional Assessment of Cancer Therapyâ€œKidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma. Value in Health, 2018, 21, 1413-1418.	0.3	7
336	Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash. Oncologist, 2019, 24, 4-8.	3.7	7
337	Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study. Clinical Genitourinary Cancer, 2021, 19, 468.e1-468.e5.	1.9	7
338	The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, 113-117.	3.8	7
339	Recent clinical development of dendritic cell-based immunotherapy for prostate cancer. Expert Opinion on Biological Therapy, 2004, 4, 1729-1734.	3.1	6
340	Determining the optimal dose and schedule of sunitinib. Cancer, 2012, 118, 1178-1180.	4.1	6
341	Pharmacokinetically Guided Dosing of Oral Drugs: True Precision Oncology?. Clinical Cancer Research, 2016, 22, 5626-5628.	7.0	6
342	Axitinib for the treatment of metastatic renal cell carcinoma. Future Oncology, 2016, 12, 303-311.	2.4	6

#	ARTICLE	IF	CITATIONS
343	Future Challenges for Drug Development in Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 577-579.	1.6	6
344	Goldilocks Dosing of TKIs: A Dose that Is Just Right Leads to Optimal Outcomes. <i>Clinical Cancer Research</i> , 2018, 24, 2979-2980.	7.0	6
345	To Treat or Not to Treat—Balancing Benefits and Risks of Treatment Delay Among Patients With Cancer During the COVID-19 Pandemic. <i>JAMA Oncology</i> , 2020, 6, 1868.	7.1	6
346	Implications of the United States Preventive Services Task Force Recommendations on Prostate Cancer Stage Migration. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e12-e16.	1.9	6
347	Association between cytoreductive nephrectomy and survival among patients with metastatic renal cell carcinoma receiving modern therapies: a systematic review and meta-analysis examining effect modification according to systemic therapy approach. <i>Cancer Causes and Control</i> , 2021, 32, 675-680.	1.8	6
348	Association of neutrophil to lymphocyte ratio (NLR) with efficacy from JAVELIN Renal 101.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5061-5061.	1.6	6
349	Meta-analysis on the association of <i>VEGFR1</i> genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients. <i>Oncotarget</i> , 2017, 8, 1204-1212.	1.8	6
350	Phase I, two-part, multicenter, first-in-human (FIH) study of DS-6000a in subjects with advanced renal cell carcinoma (RCC) and ovarian tumors (OVC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 3002-3002.	1.6	6
351	Specific immunotherapy in renal cancer: a systematic review. <i>Therapeutic Advances in Urology</i> , 2017, 9, 45-58.	2.0	5
352	Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma. <i>Targeted Oncology</i> , 2017, 12, 333-340.	3.6	5
353	CALGB 90003: Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: An Intergroup Phase II Study.. <i>Blood</i> , 2004, 104, 810-810.	1.4	5
354	The Role of Targeted Therapy in Metastatic Renal Cell Carcinoma. <i>Scientific World Journal</i> , The, 2007, 7, 800-807.	2.1	4
355	The intersection of sunitinib with the immunosuppressive microenvironment of renal cell carcinoma: implications for future therapeutics. <i>Targeted Oncology</i> , 2007, 2, 225-234.	3.6	4
356	Renal cell carcinoma: ten years of significant advances. <i>Targeted Oncology</i> , 2010, 5, 73-74.	3.6	4
357	Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma. <i>Journal of Cancer Survivorship</i> , 2011, 5, 255-262.	2.9	4
358	Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study. <i>BMC Cancer</i> , 2019, 19, 17.	2.6	4
359	Radical shifts in the first-line management of metastatic renal cell carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 71-72.	27.6	4
360	Identifying Prostate Surface Antigen Patterns of Change in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with Abiraterone and Prednisone. <i>Targeted Oncology</i> , 2020, 15, 477-483.	3.6	4

#	ARTICLE	IF	CITATIONS
361	Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma. <i>Future Oncology</i> , 2020, 16, 1199-1210.	2.4	4
362	Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts. <i>JCO Global Oncology</i> , 2020, 6, 293-306.	1.8	4
363	Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 167-175.	1.9	4
364	Editorial Comment. <i>Journal of Urology</i> , 2009, 182, 2599-2600.	0.4	3
365	The Context of Blood Vessels and Response to VEGF-Targeted Therapy. <i>Clinical Cancer Research</i> , 2013, 19, 6647-6649.	7.0	3
366	Re: Pazopanib Versus Sunitinib in Metastatic Renal-cell Carcinoma. <i>European Urology</i> , 2014, 65, 667-668.	1.9	3
367	On-treatment biomarkers in metastatic renal cell carcinoma: towards individualization of prognosis?. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 97-99.	2.4	3
368	Comparative Effectiveness of Tumor Response Assessment Methods: Standard of Care Versus Computer-Assisted Response Evaluation. <i>JCO Clinical Cancer Informatics</i> , 2017, 1, 1-16.	2.1	3
369	Identifying Institutional Causes of Delay to Radical Cystectomy among Patients with High Risk Bladder Cancer Treated at a Tertiary Referral Center Using Process Map Analysis. <i>Urology Practice</i> , 2018, 5, 383-390.	0.5	3
370	TIVO-3: Final OS analysis of a phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5062-5062.	1.6	3
371	Association between prior nephrectomy and efficacy of immune checkpoint inhibitor therapy in metastatic renal cell carcinoma - A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 64.e17-64.e24.	1.6	3
372	Review: thyroid function abnormalities in patients receiving VEGF-targeted therapy. <i>Clinical Advances in Hematology and Oncology</i> , 2011, 9, 337-8.	0.3	3
373	Clinical trials in patients with biochemically relapsed prostate cancer. <i>BJU International</i> , 2006, 97, 905-910.	2.5	2
374	Molecularly targeted therapy in renal cell carcinoma: where do we go from here?. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1753-1760.	2.4	2
375	What Is Standard Initial Systemic Therapy in Metastatic Renal Cell Carcinoma?. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 256-263.	1.9	2
376	Biology and Treatment of Advanced Renal Cell Carcinoma: A Global Perspective. <i>Seminars in Oncology</i> , 2013, 40, 419-420.	2.2	2
377	Computed Tomography Characteristics of Unresectable Primary Renal Cell Carcinoma Treated With Neoadjuvant Sunitinib. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 117-123.	1.9	2
378	Is It Safe to Restart Antivasular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia?. <i>Case Reports in Oncological Medicine</i> , 2015, 2015, 1-4.	0.3	2

#	ARTICLE	IF	CITATIONS
379	What are the prognostic factors for survival in patients with metastatic renal cell carcinoma?. Nature Clinical Practice Oncology, 2005, 2, 292-293.	4.3	1
380	Lapatinib therapy for patients with advanced renal cell carcinoma. Nature Clinical Practice Oncology, 2008, 5, 626-627.	4.3	1
381	Organ Preservation for Recurrent Urethral Adenocarcinoma With Concurrent Chemotherapy and Radiation. Urology, 2018, 113, e1-e2.	1.0	1
382	Information Transparency in the Drug Approval Process. JAMA Oncology, 2018, 4, 1621.	7.1	1
383	Are immune checkpoint combination therapies for intermediate and poor risk renal cell carcinoma better than immune checkpoint inhibitors combined with kinase inhibitors?. Lancet Oncology, The, 2021, 22, 593-594.	10.7	1
384	Practice challenges affecting optimal care as identified by US medical oncologists who treat renal cell carcinomas. Journal of Community and Supportive Oncology, 2014, 12, 197-204.	0.1	1
385	Extended therapy breaks from VEGFR TKI therapy in renal cell carcinoma: Sometimes less is more. Oncotarget, 2018, 9, 14036-14037.	1.8	1
386	Sorafenib in Advanced Renal Cancer. Drugs, 2007, 67, 484-485.	10.9	0
387	Circulating tumor cells in metastatic castration-resistant prostate cancer. Current Oncology Reports, 2009, 11, 163-164.	4.0	0
388	Editorial Comment. Urology, 2010, 75, 1114-1115.	1.0	0
389	Relapse models for clear cell renal carcinoma – Authors' reply. Lancet Oncology, The, 2015, 16, e378.	10.7	0
390	Toward individualized treatment in urologic oncology. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 170.	1.6	0
391	Changing Landscape of Refractory Renal Cell Carcinoma. Journal of Oncology Practice, 2016, 12, 422-423.	2.5	0
392	Descriptive comparison of hospital formulary decisions with published oncology valuation methods. Journal of Oncology Pharmacy Practice, 2020, 26, 891-905.	0.9	0
393	Association of the neutrophil to eosinophil ratio with response to immunotherapy-based combinations in metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2021, 39, 341-341.	1.6	0
394	Perspectives on under-representation of minority patients (pts) in clinical trials.. Journal of Clinical Oncology, 2021, 39, e18521-e18521.	1.6	0
395	PD2-3 Towards Optimal Management of Metastatic Renal Cell Carcinoma : an Update on the Role of Sunitinib as First-line Treatment. Japanese Journal of Urology, 2008, 99, 133.	0.1	0
396	Gender impact on renal cell carcinoma survival: A population-based analysis.. Journal of Clinical Oncology, 2020, 38, e17099-e17099.	1.6	0

#	ARTICLE	IF	CITATIONS
397	Data to decisions: The impact of online education on immunotherapy in advanced renal cell carcinoma.. Journal of Clinical Oncology, 2020, 38, e17076-e17076.	1.6	0
398	906â€¦Immunogenomic evaluation of clear cell renal carcinoma uncovers HK3 as a myeloid specific metabolic enzyme. , 2021, 9, A951-A951.		0
399	Phase 1b/2 umbrella study of investigational immune and targeted combination therapies for patients with advanced clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology, 2022, 40, TPS404-TPS404.	1.6	0
400	Reply to S. Tan et al. Journal of Clinical Oncology, 0, , .	1.6	0